Scientific Reports · 2015 · 257 citations · 36 references
Life SciencesNutritional SciencesPharmacologyInflammationMetabolic RegulationNutritional BiochemistryHepatotoxicity MechanismsLipid MetabolismLipid PeroxidationMetabolic InflammationActivated Hepatic Stellate CellsHepatic Insulin ResistanceHepatic Lipid AccumulationInsulin Resistance TreatmentKupffer CellsLipid AccumulationLipid Peroxidation ResistanceNonalcoholic Steatohepatitis Associated Fibrosis
Hepatic insulin resistance and nonalcoholic steatohepatitis (NASH) could be caused by excessive hepatic lipid accumulation and peroxidation. Vitamin E has become a standard treatment for NASH. However, astaxanthin, an antioxidant carotenoid, inhibits lipid peroxidation more potently than vitamin E. Here, we compared the effects of astaxanthin and vitamin E in NASH. We first demonstrated that astaxanthin ameliorated hepatic steatosis in both genetically (ob/ob) and high-fat-diet-induced obese mice. In a lipotoxic model of NASH: mice fed a high-cholesterol and high-fat diet, astaxanthin alleviated excessive hepatic lipid accumulation and peroxidation, increased the proportion of M1-type macrophages/Kupffer cells, and activated stellate cells to improve hepatic inflammation and fibrosis. Moreover, astaxanthin caused an M2-dominant shift in macrophages/Kupffer cells and a subsequent reduction in CD4(+) and CD8(+) T cell recruitment in the liver, which contributed to improved insulin resistance and hepatic inflammation. Importantly, astaxanthin reversed insulin resistance, as well as hepatic inflammation and fibrosis, in pre-existing NASH. Overall, astaxanthin was more effective at both preventing and treating NASH compared with vitamin E in mice. Furthermore, astaxanthin improved hepatic steatosis and tended to ameliorate the progression of NASH in biopsy-proven human subjects. These results suggest that astaxanthin might be a novel and promising treatment for NASH.
36
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations
Naga Chalasani, Zobair M. Younossi, Joel E. Lavine et al. · Hepatology · 2012 · 3.8K citations
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley et al. · New England Journal of Medicine · 2010 · 3.3K citations · Full text
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Giulio Marchesini, Elisabetta Bugianesi, Gabriele Forlani et al. · Hepatology · 2003 · 2.7K citations · Full text